Live Feeds
● LIVE Updated 1h ago · 12 sources tracked

Experimental Lilly combination drug tops Zepbound in weight-loss trial

Eli Lilly reported that its experimental combination drug EloraTZP outperformed Zepbound in a head-to-head mid-stage trial. Patients with diabetes receiving the highest tested dose of EloraTZP lost an average of 23.3% of their body weight, compared to 14.8% for those receiving tirzepatide alone. EloraTZP combines tirzepatide with the experimental amylin drug eloralintide. Following these results, the Indianapolis-based pharmaceutical company plans to initiate Phase 3 trials for the combination regimen by the end of 2026.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ EloraTZP combines tirzepatide and the experimental drug eloralintide.
  • ✓ Patients with diabetes on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
  • ✓ Tirzepatide alone produced 14.8% weight loss in the same Phase 2 diabetes trial.
  • ✓ Eli Lilly plans to start Phase 3 trials for the combination regimen at the end of the year.
🛡️ Source Corroboration: 12 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly released Phase 2 trial data showing EloraTZP produces greater weight loss than tirzepatide alone.

Live updates

  1. Eli Lilly combo drug EloraTZP outperforms Zepbound in weight-loss trial

    Eli Lilly reported that its experimental combination drug EloraTZP outperformed Zepbound in a head-to-head mid-stage trial. Patients with diabetes receiving the highest tested dose of EloraTZP lost an average of 23.3% of their body weight, compared to 14.8% for those receiving tirzepatide alone. EloraTZP combines tirzepatide with the experimental amylin drug eloralintide. Following these results, the Indianapolis-based pharmaceutical company plans to initiate Phase 3 trials for the combination regimen by the end of 2026.

    Why it matters

    Lilly is competing with Novo Nordisk to develop more effective obesity therapies by using multiple biological levers. This approach follows the development of retatrutide, a triple-hormone drug simulating GLP-1, GIP, and glucagon. Amylin drugs represent a new category of treatment for obesity and diabetes.

    What is confirmed

    • EloraTZP combines tirzepatide and the experimental drug eloralintide.
    • Patients with diabetes on the highest dose of EloraTZP lost an average of 23.3% of their body weight.
    • Tirzepatide alone produced 14.8% weight loss in the same Phase 2 diabetes trial.
    • Eli Lilly plans to start Phase 3 trials for the combination regimen at the end of the year.
    • Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.

    Still unconfirmed

    • Lilly stocks dropped as EloraTZP results tested tolerability.
    • Retatrutide delivers an average weight loss of 50 pounds.

    What to watch next

    • Launch of Phase 3 trials for EloraTZP at the end of 2026
    • Further data on the tolerability of the eloralintide and tirzepatide combination
    Sources used for this update (13)
    1. The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
    2. CNBC — Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
    3. arstechnica.com — Most powerful obesity drug yet: People lost up to 25% of ...
    4. Reuters — Experimental Lilly combination drug tops Zepbound in weight-loss trial
    5. USA Today — Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
    6. Fierce Biotech — Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
    7. www.biopharmadive.com — 3 takeaways from a European obesity scientific meeting | BioPharma Dive
    8. www.medicaldaily.com — Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 D....
    9. finance.yahoo.com — Experimental Lilly combination drug tops Zepbound in weight-loss trial
    10. www.cnbc.com — Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial
    11. www.gurufocus.com — Lilly Stocks Drop as EloraTZP Beats Zepbound but Tests Tolerability
    12. www.cnbc.com — Lilly, Novo bet on amylin obesity drugs after GLP-1s
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community